About Monitoring

110 CAN PIEZOELECTRIC TRANSDUCERS BE USED TO EVALUATE RESPIRATORY MECHANICS IN VENTILATED CHILDREN? ARCAS Group. V. Neve , R. Logier, Y. Riou, L. Storme, A. Martinot. F. Leclerc. University Hospital. 59037 Lille. France. Respiratory mechanics measurements are useful in mechanically ventilated children to optimize ventilator settings. Nevertheless, the transducers used to measure flow (F) and pressure (P) remain expensive. Objective. To evaluate the performances of piezoelectric P transducers (350 US Dollar) in measuring F and P. Methods. We used a previously described monitoring system measuring respiratory parameters [1]. In this study F was obtained by a differential piezoelectric P transducer (± 12.7 cmH 2O, Honeywell) whose sensitivity has been reduced to ± 2 cmH2O by an electronic amplification equipment and P by a piezoelectric P transducer (± 70.3 cmH2O, Honeywell) connected to a grid pneumotachymeter (PNT) (Fleisch 0 or 1). Volume (V) (5 to 400 ml) obtained by numeric integration of F (0.125 to 10 L/min ) and P (2 to 70 cmH2O) were respectively delivered through a calibrated seringe and an electronical manometer (Pic 400 Premier) and calculated by the computer. Bland and Altman analysis was used for assessment of results bias. Coefficient of repeatability (CR) was estimated by the standard deviation of repeated measurements of the parameters as calculated in a oneway analysis of variance. Results. Mean difference (Mdif) between injected V (5 to 50 ml) and measured V using PNT 0 was 0.15 ml, SD = 0.13 ml, Difference and mean V were not correlated. SD of repeated V measurements were not correlated to V. CR was 0.4 ml. Mdif between injected V (25 to 400 ml) and measured V using PNT 1 was 3 ml, SD = 6 ml. SD of repeated V measurements were not correlated to mean V. CR was 6 ml. Mdif between injected P and measured P was 0.3 cmH 2O, SD 0.4 cm H20. SD of repeated P measurements were not correlated to mean P. CR was 0.3 cmH20. Conclusion. Inexpensive piezoelectrical transducers can be used to measure F and P and evaluate respiratory mechanics in ventilated children. Reference. [1] Logier R et al. Proceedings of the 15th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 1993, Vol 15, 2, pp 1004-5. 112

[1]  M. Woodward,et al.  Blood glucose and risk of cardiovascular disease in the Asia Pacific region. , 2004, Diabetes care.

[2]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[3]  Liu Xinbing,et al.  Intensive insulin therapy for the critically ill patients with stress hyperglycemia , 2008 .

[4]  A. Calle-Pascual,et al.  Nontraumatic lower extremity amputations in diabetic and non-diabetic subjects in Madrid, Spain. , 1997, Diabetes & metabolism.

[5]  C. Pepine,et al.  A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial , 2004 .

[6]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[7]  L. Abraham,et al.  Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. , 2005, American journal of epidemiology.

[8]  B. Brenner,et al.  Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. , 2004, Diabetes care.

[9]  A. Beydoun,et al.  Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial , 1999 .

[10]  Caroline A Crowther,et al.  Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. , 2005, The New England journal of medicine.

[11]  U. Kabadi,et al.  Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. , 1996, Archives of internal medicine.

[12]  H. Yki-Järvinen,et al.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. , 2000, Diabetes care.

[13]  D. Bennett,et al.  Blood pressure and cardiovascular disease in the Asia Pacific region. , 2003, Journal of hypertension.

[14]  K. Kosaka,et al.  Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. , 2005, Diabetes research and clinical practice.

[15]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[16]  R. Dubner,et al.  Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood , 1987, Neurology.

[17]  M. Weir,et al.  An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study , 2004, Diabetologia.

[18]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[19]  J Herlitz,et al.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.

[20]  E. Barrett-Connor,et al.  Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. , 2002, Archives of internal medicine.

[21]  K. Alberti,et al.  The Care of the Diabetic Patient During Surgery , 2004 .

[22]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[23]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[24]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[25]  M J Koziel,et al.  Pulmonary complications of diabetes mellitus. Pneumonia. , 1995, Infectious disease clinics of North America.

[26]  P. Small,et al.  Tuberculosis and diabetes in southern Mexico. , 2004, Diabetes care.

[27]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[28]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[29]  W. Reitsma,et al.  Walking training for intermittent claudication in diabetes. , 1999, Diabetes care.

[30]  D. Feig,et al.  Type 2 diabetes in pregnancy: a growing concern , 2002, The Lancet.

[31]  M. C. Leske,et al.  The prevalence of diabetic retinopathy among adults in the United States. , 2004, Archives of ophthalmology.

[32]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[33]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[34]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[35]  G. A. Holloway,et al.  Prevention of amputation by diabetic education. , 1989, American journal of surgery.